State of Wyoming Takes Position in Guardant Health, Inc. $GH

State of Wyoming acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 10,890 shares of the company’s stock, valued at approximately $567,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Castleark Management LLC bought a new stake in Guardant Health in the 2nd quarter worth approximately $6,326,000. Nikko Asset Management Americas Inc. boosted its stake in shares of Guardant Health by 49.6% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 2,030,428 shares of the company’s stock worth $105,623,000 after buying an additional 673,438 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of Guardant Health by 8.1% in the second quarter. CANADA LIFE ASSURANCE Co now owns 32,485 shares of the company’s stock worth $1,694,000 after acquiring an additional 2,421 shares during the period. Tower Research Capital LLC TRC increased its position in Guardant Health by 284.5% during the second quarter. Tower Research Capital LLC TRC now owns 15,087 shares of the company’s stock valued at $785,000 after acquiring an additional 11,163 shares during the last quarter. Finally, Meridiem Capital Partners LP bought a new position in Guardant Health in the second quarter valued at about $2,643,000. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Evercore ISI boosted their price target on Guardant Health from $68.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Wells Fargo & Company raised their price objective on shares of Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday. Wolfe Research raised shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 target price for the company in a report on Thursday, September 25th. Canaccord Genuity Group set a $100.00 price target on shares of Guardant Health in a research report on Thursday, October 30th. Finally, BTIG Research lifted their price target on shares of Guardant Health from $100.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $94.57.

Guardant Health Stock Up 0.6%

NASDAQ GH opened at $102.67 on Tuesday. Guardant Health, Inc. has a twelve month low of $29.91 and a twelve month high of $112.43. The business has a 50-day moving average price of $89.50 and a 200-day moving average price of $66.16. The firm has a market cap of $12.94 billion, a price-to-earnings ratio of -31.98 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. During the same period in the previous year, the firm earned ($0.88) earnings per share. The business’s revenue was up 38.5% on a year-over-year basis. Research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Activity

In other news, Director Ian T. Clark sold 28,611 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $107.19, for a total value of $3,066,813.09. Following the transaction, the director owned 9,851 shares of the company’s stock, valued at approximately $1,055,928.69. The trade was a 74.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Medina Manuel Hidalgo sold 1,250 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $105.00, for a total transaction of $131,250.00. Following the transaction, the director owned 797 shares of the company’s stock, valued at approximately $83,685. This represents a 61.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 330,673 shares of company stock valued at $34,534,618. Company insiders own 6.10% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.